Tirzepatide

SEP 11, 2026 · PHASE 2 TRIAL

A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

ClinicalTrials.gov

Phase 2 registry record with completed enrollment but no results posted; insufficient to assess efficacy or safety, only study design and conduct are known.

SEP 11, 2026 · PHASE EARLY PHASE 1 TRIAL

Tirzepatide in Obesity-Driven Endometrial Cancer

ClinicalTrials.gov

This is an early-phase, uncontrolled window-of-opportunity study with a planned sample of 20 patients examining a mechanistic hypothesis in a pre-operative setting; no results are yet reported.

SEP 9, 2026 · PHASE 2 TRIAL

Efficacy and Safety of Tirzepatide Versus Placebo or Lisdexamfetamine Dimesylate for Binge-Eating Disorder

ClinicalTrials.gov

Phase 2 trial registration with no results posted; study is actively recruiting and designed to assess efficacy and safety of tirzepatide in binge-eating disorder.

SEP 8, 2026 · PHASE 4 TRIAL

A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)

ClinicalTrials.gov

This is a Phase 4 registry record with no reported results; it describes a planned interventional study in active recruitment with estimated enrollment of 200 participants and dual primary outcomes at 12 months.

SEP 8, 2026 · PHASE 2 TRIAL

A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

ClinicalTrials.gov

This is a Phase 2 master protocol study registration with no results reported; enrollment is ongoing and primary outcomes are allocation metrics, not efficacy or safety findings.

SEP 4, 2026 · PHASE 3 TRIAL

Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

ClinicalTrials.gov

This is a Phase 3 registry record with no reported results; the study is actively recruiting and designed to test a combination approach in a dual-disease population, but outcomes remain unreported.

AUG 26, 2026 · REGULATORY LABEL UPDATE

FDA supplemental approval: Zepbound (Efficacy)

U.S. Food and Drug Administration

FDA supplemental approval action for tirzepatide (Zepbound) efficacy; regulatory decisions do not themselves constitute clinical evidence and do not report trial outcomes.

AUG 12, 2026 · PHASE 1/2 TRIAL

A Study to Evaluate ALN-2232 in Participants With Obesity

ClinicalTrials.gov

This is a Phase 1/2 registry record for a planned interventional study with no results reported; enrollment is ongoing and no efficacy or safety data are available.